From the NICE website:
“The guidance recommends adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira UK; Remsima,Napp Pharmaceuticals ) ii, certolizumab pegol (Cimzia, UCB Pharma), golimumab (Simponi, Merck Sharp & Dohme), tocilizumab (RoActemra, Roche) and abatacept (Orencia, Bristol-Myers Squibb), each in combination with methotrexate.
Adalimumab, etanercept, certolizumab pegol or tocilizumab are also recommended as monotherapy for people who cannot take methotrexate.
In the case of certolizumab pegol, golimumab, abatacept and tocilizumab the recommendation is subject to the companies providing them as agreed in their patient access schemes.
The guidance states that treatment should be started with the least expensive drug (taking into account administration costs, dose needed and product price per dose).”
|Image: My Arthritis|